Veradermics, a Phase 3-ready biotech developing therapies for hair loss, announced terms for its IPO on Wednesday.
The New Haven, CT-based company plans to raise $200 million by offering 13.4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Veradermics would command a market cap of $509 million.
Veradermics Therapeutics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing an oral, non-hormonal extended-release formulation of minoxidil (VDPHL01) to address male and female pattern hair loss affecting approximately 50 million men and 30 million women in the United States. The company has fully enrolled a 519-patient Phase 2-3 trial in male patients and has initiated two additional registration-directed, randomized, double-blind, placebo-controlled Phase 3 trials targeting 498 male patients and 552 female patients to support a 505(b)(2) NDA.
Veradermics was founded in 2019 and plans to list on the NYSE under the symbol MANE. Jefferies, Leerink Partners, Citi, and Cantor Fitzgerald are the joint bookrunners on the deal. It is expected to price on February 3rd, 2026.
